Skip to main content

Advertisement

Table 1 Demographic and clinical characteristics

From: SERT-to-DAT ratios in early Parkinson’s disease do not correlate with the development of dyskinesias

  PDNDYS(n= 27) PDDYS(n= 23) P value
Age of onset PD (mean ± SD) (year) 56.8 ± 6.8 49.7 ± 10.9 0.002
Male sex number (percent) 15 (56) 16 (70) 0.39
Total follow-up (mean ± SD) (months) 155 ± 49 190 ± 29 0.004
Most affected side (striatal) (right/left) 11/16 11/12 0.43
Disease duration (mean ± SD) (year) 12.8 ± 4.1 15.8 ± 2.4 0.003
Disease duration until levodopa use (median, ICR) (year) 3.0, 4.75 2.4, 2.6 0.57
Disease duration until onset dyskinesias (mean ± SD) (year) NA 7.8 ± 3.9 NA
Levodopa use until onset dyskinesias (mean ± SD) (year) NA 5.1 ± 3.0 NA
Levodopa use (mean ± SD) (year) 9.5 ± 3.4 13.2 ± 2.0 <0.001
UPDRS motor score at moment of imaging 16.9 ± 6.4 21.4 ± 5.1 0.008
(total range, 0 to 108) (mean ± SD)    
Subscore A (0 to 88) 10.8 ± 3.4 14.2 ± 3.4 0.001
Subscore B (0 to 20) 6.1 ± 3.9 7.2 ± 2.8 0.25
Modified HY score at moment of imaging (1/1.5/2/2.5) 7/3/8/9 6/1/9/7 0.79
  1. PD Parkinson’s disease, PD NDYS PD patients subgroup that did not develop dyskinesias, PD DYS PD patients subgroup that did develop dyskinesias, SD standard deviation, ICR interquartile range, NA data not available, UPDRS unified Parkinson’s disease rating scale, UPDRS subscore A, consists of dopaminergic symptoms, subscore B, consists of non-dopaminergic symptoms, HY Hoehn and Yahr.